8-K: Immunic Transfers to Nasdaq Capital Market Amid Bid Price Rule Non-Compliance

Immunic, Inc. has transferred its common stock listing to the Nasdaq Capital Market after failing to meet the $1.00 minimum bid price requirement, gaining an extended grace period until June 22, 2026.

Summary

• Immunic, Inc. (IMUX) received approval on January 5, 2026, to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market.
• The transfer of common stock will be effective at the opening of business on January 7, 2026, and will continue to trade under the symbol IMUX.
• The Company previously received a letter on June 27, 2025, from Nasdaq indicating non-compliance with Listing Rule 5450(a)(1) because its common stock bid price closed below $1.00 for 30 consecutive business days.
• Immunic failed to regain compliance with the Bid Price Rule by the initial 180-day grace period deadline of December 24, 2025.
• As a result of the transfer approval, Immunic has been granted an additional 180-day grace period, until June 22, 2026, to regain compliance.
• To regain compliance, the common stock's minimum bid price must be at least $1.00 for at least 10 consecutive business days on or prior to June 22, 2026.
• As a condition of the approval, Immunic notified Nasdaq that it would seek to implement a reverse stock split, if necessary, to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's non-compliance with Nasdaq listing rules and the subsequent transfer to a lower-tier market. While an extension has been granted, the underlying issue of low stock price persists, and a reverse stock split is a potential negative catalyst. This indicates ongoing challenges in market valuation and investor confidence.

Positives

• The approval to transfer to the Nasdaq Capital Market grants Immunic an additional 180-day grace period, extending its opportunity to regain compliance with the minimum bid price rule and avoid immediate delisting.
• The Nasdaq Capital Market operates similarly to the Nasdaq Global Select Market, and listed companies must still meet financial and corporate governance requirements, maintaining a level of market integrity.

Negatives

• Immunic failed to maintain the Nasdaq Global Select Market's minimum bid price requirement of $1.00, leading to a transfer to a lower-tier market.
• The Company did not regain compliance by the initial deadline of December 24, 2025, indicating persistent challenges with its stock price.
• The potential necessity of a reverse stock split to regain compliance could lead to a reduction in the number of outstanding shares and may be perceived negatively by investors due to historical associations with struggling companies.

Risks

• Failure to regain compliance with the $1.00 minimum bid price rule by June 22, 2026, could lead to Nasdaq notifying the Company of its determination to delist its common stock.
• While the Company can appeal a delisting determination, there is no assurance that a Nasdaq Listing Qualifications Panel would grant a request for continued listing.
• The implementation of a reverse stock split, if necessary, carries risks such as potential further stock price decline post-split or a negative market perception.

Future Outlook

Immunic's immediate future outlook is focused on regaining compliance with Nasdaq's $1.00 minimum bid price rule by June 22, 2026. The Company has indicated it will consider a reverse stock split if necessary to achieve this compliance. Failure to do so could result in delisting from Nasdaq.

Industry Context

The transfer of a company's listing to a lower-tier market like the Nasdaq Capital Market due to bid price non-compliance is a common occurrence for smaller biotechnology or emerging growth companies. It often signals challenges in market valuation and investor confidence, potentially impacting the company's ability to attract institutional investment and maintain liquidity. While the Capital Market still offers a regulated trading environment, it typically has less stringent listing requirements and may be perceived as a step down from the Global Select Market.

Stakeholder Impact

• Shareholders face increased uncertainty regarding the company's long-term listing status and potential dilution if a reverse stock split is implemented.
• The transfer to the Nasdaq Capital Market may reduce the company's visibility and liquidity, potentially impacting investor interest and trading volumes.
• The need for a reverse stock split could negatively affect investor sentiment and the perceived value of their holdings.

Next Steps

• Regain compliance with Nasdaq's $1.00 minimum bid price rule by June 22, 2026.
• Consider and potentially implement a reverse stock split if necessary to meet the bid price requirement.

Key Dates

Recommendation

While the transfer to the Nasdaq Capital Market provides a temporary reprieve and an extended grace period, the underlying issue of non-compliance with the minimum bid price rule remains unresolved. The potential for a reverse stock split introduces further uncertainty and is often viewed as a negative signal. Investors should hold to monitor the company's progress in regaining compliance and assess the impact of any potential reverse stock split, as the immediate future carries significant risk of further price volatility or delisting.

Keywords

Immunic, IMUX, Nasdaq, Delisting, Bid Price Rule, Nasdaq Capital Market, Reverse Stock Split, Compliance, SEC 8-K